AP 5280

Drug Profile

AP 5280

Alternative Names: AP 5070; AP5280; Polymer Platinate

Latest Information Update: 26 Apr 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of London School of Pharmacy
  • Developer Access Pharmaceuticals
  • Class Antineoplastics; Platinum complexes
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Ovarian cancer

Most Recent Events

  • 26 Nov 2002 Phase-I/II clinical trials in Ovarian cancer in Europe (unspecified route)
  • 11 Sep 2000 Phase-I clinical trials for Solid tumours in Europe (unspecified route)
  • 16 Aug 2000 Preclinical data has been added to the pharmacodynamics and pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top